Philippe Mellet

Dr. Philippe Mellet

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
NJNatacha Jugniot
Natacha Jugniot
IDIndranil Duttagupta
Indranil Duttagupta
ARAngélique Rivot
Angélique Rivot
PMPhilippe Massot
Philippe Massot
CCColleen Cardiet
Colleen Cardiet
PMPhilippe Mellet
Philippe Mellet

5 July 2023 in Progress in Polymer Science
Verified
Journal Article
Closed access
GAGerard Audran
Gerard Audran
Elena BagryanskayaElena Bagryanskaya
Elena Bagryanskaya
RBRaphaël Bikanga
Raphaël Bikanga
MCMichelle L. Coote
Michelle L. Coote
OGOlga Guselnikova
Olga Guselnikova
PPPavel Postnikov
Pavel Postnikov

26 September 2019 in Organic Chemistry Frontiers
Verified
Journal Article
Closed access
PDF file
GAGerard Audran
Gerard Audran
LBLionel Bosco
Lionel Bosco
PBPaul Brémond
Paul Brémond
NJNatacha Jugniot
Natacha Jugniot
Sylvain R.A. MarqueSylvain R.A. Marque
Sylvain R.A. Marque
TYToshihide Yamasaki
Toshihide Yamasaki
Alkoxyamine 1 is selectively hydrolyzed by chymotrypsin and substilisin A into alkoxyamine 2H+ for which C–ON bond homolysis occurred with a 4-fold increase in rate constants compared to 1 while non-specific proteases had no effect. This highlights the triggering effect of enzymes. This is a proof of concept for a theranostic approach for treating solid tumors using enzyme-activated alkoxyamines releasing a cytotoxic alkyl radical and a stable nitroxide as a contrast agent for Overhauser-enhanced MRI.

30 July 2020 in Organic Chemistry Frontiers
Verified
Journal Article
Open access
PDF file
MAMuriel Albalat
Muriel Albalat
GAGerard Audran
Gerard Audran
MHMaxence Holzritter
Maxence Holzritter
Sylvain R.A. MarqueSylvain R.A. Marque
Sylvain R.A. Marque
PMPhilippe Mellet
Philippe Mellet
PVPierre Voisin
Pierre Voisin
The potential of alkoxyamines as theranostic agents has been recently promoted by our groups. The success of such an approach relies on the switch upon enzymatic triggering between highly stable precursor alkoxyamines and activated alkoxyamines exhibiting fast homolysis of the C–ON bond. Hence, at 37 °C in water, benzyl 2-(2,2,6,6-tetramethylpiperidin-N-oxy)-3-ethoxy-3-acetoxypropanoate and benzyl 2-ditert-butylaminoxy-3-ethoxy-3-acetoxy propanoate afford tmax of 2000 s (35% conversion) and 500 s (60% conversion), respectively, for the C–ON bond homolysis in the presence of Subtilisin A whereas t1/2 of ca. 42 thousand millenniums and 330 years are expected accordingly to Ea values in n-propanol. These results nicely highlight the on/off switch, provided that an enzymatic activity controls the C–ON bond homolysis.

28 June 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SSSeda Seren
Seda Seren
JJJean-Patrick Joly
Jean-Patrick Joly
PVPierre jean Voisin
Pierre jean Voisin
VBVéronique Bouchaud
Véronique Bouchaud
GAGérard Audran
Gérard Audran
PMPhilippe Mellet
Philippe Mellet
Current chemotherapies suffer low specificity and sometimes drug resistance. Neutrophil elastase activity in cancer is associated with poor prognosis and metastasis settlement. More generally, tumors harbor various and persistent protease activities unseen in healthy tissues. In an attempt to be more specific, we designed prodrugs that are activatable by neutrophil elastase. Upon activation, these alkoxyamine-based drugs release cytotoxic alkyl radicals that act randomly to prevent drug resistance. As a result, U87 glioblastoma cells displayed high level caspase 3/7 activation during the first hour of exposure in the presence of human neutrophil elastase and the prodrug in vitro. The apoptosis process and cell death occurred between 24 and 48 h after exposure with a half lethal concentration of 150 μM. These prodrugs are versatile and easy to synthetize and can be adapted to many enzymes.

12 June 2019 in Contrast Media & Molecular Imaging
Verified
Journal Article
Open access
PDF file
NJNatacha Jugniot
Natacha Jugniot
PVPierre Voisin
Pierre Voisin
ABAbderrazzak Bentaher
Abderrazzak Bentaher
PMPhilippe Mellet
Philippe Mellet
The last few decades of protease research has confirmed that a number of important biological processes are strictly dependent on proteolysis. Neutrophil elastase (NE) is a critical protease in immune response and host defense mechanisms in both physiological and disease-associated conditions. Particularly, NE has been identified as a promising biomarker for early diagnosis of lung inflammation. Recent studies have shown an increasing interest in developing methods for NE activity imaging both in vitro and in vivo. Unlike anatomical imaging modalities, functional molecular imaging, including enzymatic activities, enables disease detection at a very early stage and thus constitutes a much more accurate approach. When combined with advanced imaging technologies, opportunities arise for measuring imbalanced proteolytic activities with unprecedented details. Such technologies consist in building the highest resolved and sensitive instruments as well as the most specific probes based either on peptide substrates or on covalent inhibitors. This review outlines strengths and weaknesses of these technologies and discuss their applications to investigate NE activity as biomarker of pulmonary inflammatory diseases by imaging.